Optimization of a novel antimalarial drug candidate for plant-scale synthesis

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43AI100353-01
Agency Tracking Number: R43AI100353
Amount: $102,614.00
Phase: Phase I
Program: SBIR
Awards Year: 2012
Solitcitation Year: 2012
Solitcitation Topic Code: NIAID
Solitcitation Number: PA09-113
Small Business Information
DESIGNMEDIX, INC.
2828 Corbett Ave Suite 140A, PORTLAND, OR, 97201-4830
Duns: 623389009
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 STEVEN BURGESS
 (503) 484-7026
 sburgess@designmedix.com
Business Contact
 SANDRA SHOTWELL
Phone: (503) 771-0173
Email: shotwell@designmedix.com
Research Institution
 Stub
Abstract
DESCRIPTION (provided by applicant): There is a great need for anti-malarial drugs that are inexpensive and effective against drug-resistant strains. Malaria is one of the most important diseases worldwide, with over 225 million cases each year, and about800 thousand deaths. Most of these deaths occur in sub-Saharan Africa among the more vulnerable groups, such as children and pregnant women. In addition to the fatalities, malaria imparts a huge economic burden on the endemic countries, many of which are also the world's poorest. In some of the worst affected countries as much as 40% of their total health expenditure is spent on malaria, as current drug treatments are expensive. Although there are several approved antimalarial drugs, the malaria parasite asa great ability to develop resistance, to such an extent that drug resistance has been identified to every current therapy. This drug resistance can be sufficiently strong as to render the drug almost ineffective, as is the case with chloroquine, once the'gold star' treatment for malaria. DesignMedix has developed a novel set of antimalarial compounds, the lead of which is currently undergoing preclinical trials. The goal of this proposal is to optimize the synthesis of the lead compound, developing the method from a research laboratory scale, to one ready for plant-scale production. The aim is to improve the yields and reduce production costs in an effort to keep the overall cost of the drug as low as possible and therefore affordable to those who need it. PUBLIC HEALTH RELEVANCE: Malaria is a parasitic disease which kills around 800 thousand people each year, mainly children and pregnant women in sub-Saharan Africa. The parasite has a great ability to develop drug resistance, such that currentlythere are strains resistant to ever approved drug, so there is a continuing need for new therapies that are less expensive than current drugs. This work is to develop a novel antimalarial drug, from research laboratory scale to a method suitable for fullscale production.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government